European Journal of Cancer

Papers
(The H4-Index of European Journal of Cancer is 55. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-11-01 to 2024-11-01.)
ArticleCitations
The European cancer burden in 2020: Incidence and mortality estimates for 40 countries and 25 major cancers330
Mortality in patients with cancer and coronavirus disease 2019: A systematic review and pooled analysis of 52 studies254
Global, regional and national burden of primary liver cancer by subtype172
Preoperative pembrolizumab combined with chemoradiotherapy for oesophageal squamous cell carcinoma (PALACE-1)165
Skin cancer classification via convolutional neural networks: systematic review of studies involving human experts148
Consensus on molecular imaging and theranostics in neuroendocrine neoplasms144
European consensus-based interdisciplinary guideline for melanoma. Part 1: Diagnostics: Update 2022134
European consensus-based interdisciplinary guideline for melanoma. Part 2: Treatment - Update 2022131
Risk factors for Coronavirus Disease 2019 (COVID-19) severity and mortality among solid cancer patients and impact of the disease on anticancer treatment: A French nationwide cohort study (GCO-002 CAC126
Evidence-based recommendations on categories for extent of resection in diffuse glioma118
Comparative assessment of early mortality risk upon immune checkpoint inhibitors alone or in combination with other agents across solid malignancies: a systematic review and meta-analysis117
Ultrasound-based deep learning radiomics in the assessment of pathological complete response to neoadjuvant chemotherapy in locally advanced breast cancer116
Neoadjuvant therapy or upfront surgery for resectable and borderline resectable pancreatic cancer: A meta-analysis of randomised controlled trials113
Evolution of low HER2 expression between early and advanced-stage breast cancer108
Selenium stimulates the antitumour immunity: Insights to future research106
The immune landscape of neuroblastoma: Challenges and opportunities for novel therapeutic strategies in pediatric oncology106
Deficient mismatch repair/microsatellite unstable colorectal cancer: Diagnosis, prognosis and treatment103
Late-onset and long-lasting immune-related adverse events from immune checkpoint-inhibitors: An overlooked aspect in immunotherapy102
Clinical practice guidelines for BRCA1 and BRCA2 genetic testing97
Gastrointestinal cancer classification and prognostication from histology using deep learning: Systematic review95
Immunogenicity and risk of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection after Coronavirus Disease 2019 (COVID-19) vaccination in patients with cancer: a systematic review and92
Exosomes and exosomal RNAs in breast cancer: A status update91
Tertiary lymphoid structures marker CXCL13 is associated with better survival for patients with advanced-stage bladder cancer treated with immunotherapy91
A systematic review and meta-analysis: the effect of active cancer treatment on severity of COVID-1989
Avapritinib in unresectable or metastatic PDGFRA D842V-mutant gastrointestinal stromal tumours: Long-term efficacy and safety data from the NAVIGATOR phase I trial86
Effect of concomitant medications with immune-modulatory properties on the outcomes of patients with advanced cancer treated with immune checkpoint inhibitors: development and validation of a novel pr82
Applications of single-cell and bulk RNA sequencing in onco-immunology79
Intratumour microbiome associated with the infiltration of cytotoxic CD8+ T cells and patient survival in cutaneous melanoma78
Diagnosis and treatment of Merkel cell carcinoma: European consensus-based interdisciplinary guideline – Update 202275
Sentinel lymph node biopsy and morbidity outcomes in early cervical cancer: Results of a multicentre randomised trial (SENTICOL-2)75
Immune-based combinations for the treatment of metastatic renal cell carcinoma: a meta-analysis of randomised clinical trials75
Interleukin-6 blockade for prophylaxis and management of immune-related adverse events in cancer immunotherapy71
Immune checkpoint inhibitors in treatment of soft-tissue sarcoma: A systematic review and meta-analysis69
High-intensity statins are associated with improved clinical activity of PD-1 inhibitors in malignant pleural mesothelioma and advanced non-small cell lung cancer patients69
Real world data of cemiplimab in locally advanced and metastatic cutaneous squamous cell carcinoma69
Perspectives on natural compounds in chemoprevention and treatment of cancer: an update with new promising compounds69
Lenvatinib, toripalimab plus hepatic arterial infusion chemotherapy in patients with high-risk advanced hepatocellular carcinoma: A biomolecular exploratory, phase II trial67
Combining CNN-based histologic whole slide image analysis and patient data to improve skin cancer classification66
Repurposing anticancer drugs for the management of COVID-1965
Dutch Oncology COVID-19 consortium: Outcome of COVID-19 in patients with cancer in a nationwide cohort study64
Explainable artificial intelligence in skin cancer recognition: A systematic review62
Atezolizumab plus bevacizumab versus lenvatinib for unresectable hepatocellular carcinoma: a large real-life worldwide population62
High mortality among hospital-acquired COVID-19 infection in patients with cancer: A multicentre observational cohort study62
Updated efficacy and safety of KEYNOTE-224: a phase II study of pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib61
Long-term safety of pembrolizumab monotherapy and relationship with clinical outcome: A landmark analysis in patients with advanced melanoma61
Effect of corticosteroids on the outcome of patients with advanced non–small cell lung cancer treated with immune-checkpoint inhibitors59
How to manage patients with corticosteroids in oncology in the era of immunotherapy?58
Immune scores in colorectal cancer: Where are we?58
Epidemiology of cutaneous melanoma and keratinocyte cancer in white populations 1943–203658
Definition of oligometastatic esophagogastric cancer and impact of local oligometastasis-directed treatment: A systematic review and meta-analysis57
Baseline co-medications may alter the anti-tumoural effect of checkpoint inhibitors as well as the risk of immune-related adverse events56
Reproducible safety and efficacy of atezolizumab plus bevacizumab for HCC in clinical practice: Results of the AB-real study56
The Pan-Immune-Inflammation Value in microsatellite instability–high metastatic colorectal cancer patients treated with immune checkpoint inhibitors56
Generating human prostate cancer organoids from leukapheresis enriched circulating tumour cells55
Management of patients with advanced prostate cancer—metastatic and/or castration-resistant prostate cancer: Report of the Advanced Prostate Cancer Consensus Conference (APCCC) 202255
0.041997194290161